Short Interest in Context Therapeutics Inc. (NASDAQ:CNTX) Increases By 11.8%

Context Therapeutics Inc. (NASDAQ:CNTXGet Free Report) was the target of a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 50,200 shares, a growth of 11.8% from the October 15th total of 44,900 shares. Based on an average trading volume of 35,600 shares, the short-interest ratio is presently 1.4 days. Approximately 0.4% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Maxim Group started coverage on Context Therapeutics in a research report on Monday, September 11th. They issued a “buy” rating and a $4.00 target price for the company. HC Wainwright upgraded shares of Context Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective for the company in a report on Wednesday, November 1st.

Read Our Latest Stock Report on CNTX

Institutional Investors Weigh In On Context Therapeutics

Institutional investors have recently made changes to their positions in the stock. State Street Corp bought a new position in shares of Context Therapeutics during the second quarter worth about $39,000. Northern Trust Corp acquired a new position in shares of Context Therapeutics in the 2nd quarter worth approximately $49,000. Atria Wealth Solutions Inc. bought a new stake in shares of Context Therapeutics in the 2nd quarter valued at $51,000. Renaissance Technologies LLC increased its position in shares of Context Therapeutics by 47.4% during the second quarter. Renaissance Technologies LLC now owns 28,300 shares of the company’s stock worth $45,000 after buying an additional 9,100 shares during the period. Finally, Clear Harbor Asset Management LLC bought a new position in Context Therapeutics during the second quarter worth $58,000. Institutional investors own 14.03% of the company’s stock.

Context Therapeutics Price Performance

Shares of Context Therapeutics stock traded down $0.01 during trading on Friday, hitting $1.00. The company’s stock had a trading volume of 12,922 shares, compared to its average volume of 623,241. The stock has a market cap of $15.97 million, a price-to-earnings ratio of -0.78 and a beta of 2.51. Context Therapeutics has a 52 week low of $0.47 and a 52 week high of $1.69. The stock has a 50-day moving average price of $1.14 and a two-hundred day moving average price of $1.09.

Context Therapeutics Company Profile

(Get Free Report)

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Featured Articles

Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with's FREE daily email newsletter.